+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

CRISPR and Cas Genes - Global Strategic Business Report

  • PDF Icon

    Report

  • 174 Pages
  • April 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6069872
The global market for CRISPR and Cas Genes was estimated at US$5.1 Billion in 2024 and is projected to reach US$13.2 Billion by 2030, growing at a CAGR of 17.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the CRISPR and Cas Genes market.

Global CRISPR and Cas Genes Market - Key Trends & Drivers Summarized

Why Is CRISPR Technology Revolutionizing Biotechnology? Exploring the Rise of Gene Editing

The global CRISPR and Cas genes market has seen exponential growth, driven by groundbreaking advancements in genetic engineering, biomedical research, and agricultural biotechnology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a game-changing tool, enabling precise gene editing with unprecedented accuracy and efficiency. The increasing focus on gene therapy for treating genetic disorders, cancer, and rare diseases has propelled investment in CRISPR-based applications. Additionally, agricultural biotechnology firms are leveraging CRISPR for crop improvement, disease resistance, and enhanced food production efficiency. The expanding field of synthetic biology and the development of personalized medicine have further strengthened market demand, with CRISPR playing a crucial role in targeted genetic modifications.

Which CRISPR Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR and Cas genes market is segmented into various applications, each catering to specific scientific and medical advancements. Gene therapy remains one of the most promising applications, with CRISPR being used to correct genetic mutations responsible for inherited disorders such as sickle cell anemia and cystic fibrosis. Agricultural biotechnology is another key segment, where CRISPR is revolutionizing crop development by enhancing drought resistance, disease tolerance, and nutritional content. The rise of CRISPR-based diagnostics has also gained traction, particularly in detecting infectious diseases, including COVID-19. Additionally, the field of drug discovery is benefiting from CRISPR’s ability to create genetically engineered cell models, improving pharmaceutical research and development. The development of CRISPR-based biomanufacturing solutions for synthetic biology and industrial applications has further diversified market opportunities.

How Is Innovation Driving the CRISPR Market? The Role of AI, Automation & Ethical Considerations

The CRISPR market is evolving rapidly with continuous innovations in AI-powered gene editing, automation in genetic screening, and ethical advancements in genome modification. AI-driven bioinformatics tools have enhanced CRISPR efficiency, enabling researchers to predict off-target effects and optimize gene-editing accuracy. The development of next-generation Cas proteins, such as Cas12 and Cas13, has expanded CRISPR’s versatility, allowing for RNA-based modifications and improved specificity. Additionally, the automation of CRISPR workflows through robotic lab systems has accelerated research productivity, reducing manual intervention and increasing throughput. Ethical considerations surrounding gene editing, particularly in human germline modifications, have prompted regulatory frameworks and bioethical discussions to ensure responsible research practices. The emergence of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR Market? Key Market Influencers Explained

The growth in the CRISPR and Cas genes market is driven by increasing investment in genetic research, expanding applications in medicine and agriculture, and continuous technological advancements. The rise of precision medicine has fueled demand for CRISPR-based therapies, offering personalized treatment solutions for genetic disorders and cancer. Additionally, government funding and academic research initiatives have accelerated innovation in CRISPR-based drug discovery and disease modeling. The agricultural sector’s growing need for climate-resilient crops has further boosted CRISPR adoption, providing sustainable solutions for food security challenges. The expansion of biotech startups and partnerships between pharmaceutical companies and research institutions has strengthened market competitiveness. However, ethical and regulatory considerations remain a critical factor, influencing the pace of CRISPR commercialization. With ongoing scientific breakthroughs and evolving regulatory landscapes, the global CRISPR and Cas genes market is expected to witness transformative growth, unlocking new possibilities in genetic engineering and personalized healthcare.

Report Scope

The report analyzes the CRISPR and Cas Genes market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product & Service (Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis, Screening Services); Application (Biomedical Application, Agricultural Application); End-Use (Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Kits & Reagents segment, which is expected to reach US$4.2 Billion by 2030 with a CAGR of a 19.0%. The Libraries segment is also set to grow at 18.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 16.3% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global CRISPR and Cas Genes Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global CRISPR and Cas Genes Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global CRISPR and Cas Genes Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Addgene, Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Cellectis and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 34 Featured):

  • Addgene
  • Agilent Technologies
  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • CRISPR Therapeutics
  • Editas Medicine
  • GenScript
  • Horizon Discovery (PerkinElmer)
  • Integrated DNA Technologies (IDT)
  • Intellia Therapeutics
  • Locus Biosciences
  • Mammoth Biosciences
  • Merck KGaA
  • New England Biolabs
  • Origene Technologies
  • Sangamo Therapeutics
  • Synthego Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • CRISPR and Cas Genes - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Investment in Gene Editing and Biotechnology Research Spurs Growth in CRISPR and Cas Gene Technologies
  • Surge in Precision Medicine Applications Strengthens the Business Case for CRISPR-Based Therapeutics
  • Rising Demand for Genomic Agriculture Drives Adoption of CRISPR and Cas Genes in Crop Improvement
  • Expansion of Clinical Trials and Gene Therapy Development Generates Accelerated Demand for CRISPR-Cas9 Solutions
  • Technological Advancements in CRISPR/Cas Precision and Efficiency Propel Market Growth in Therapeutic Applications
  • Regulatory Advancements and Easing of Gene Editing Guidelines Expands Market Opportunity for CRISPR-Based Products
  • Rising Focus on Hereditary Disease Treatment and Prevention Accelerates Market Adoption of CRISPR Gene Therapy Solutions
  • Increased Public Awareness of Gene Editing Capabilities and Ethics Throws the Spotlight on Transparent and Responsible CRISPR Applications
  • Growing Investment from Venture Capital and Pharma Companies Strengthens the Case for CRISPR as a Mainstream Technology
  • Expansion of Biopharmaceutical Companies Leveraging CRISPR for Drug Discovery and Development Drives Market Growth
  • Rising Global Demand for Sustainable Agricultural Practices Drives Adoption of CRISPR-Cas Genes in Food Production
  • The Need for Rapid and Cost-Effective Diagnostic Tools Accelerates Demand for CRISPR in Point-of-Care Diagnostics
  • Ongoing Advancements in CRISPR Delivery Systems Drive Adoption of CRISPR Technologies in Clinical and Agricultural Markets
  • Increasing Prevalence of Genetic Disorders and Chronic Diseases Propels the Need for CRISPR-Cas9 Solutions in Healthcare
  • Surge in Ethical and Regulatory Debates Over Germline Editing Impacts Market Expansion and Adoption in Certain Regions
  • Integration of CRISPR with Artificial Intelligence for Drug Development and Personalized Medicine Expands Addressable Market Opportunity
  • The Rise of Gene Drives for Environmental and Pest Control Applications Generates New Market Opportunities for CRISPR Technologies
  • Growing Focus on Environmental Sustainability Strengthens the Case for CRISPR in Bioremediation and Waste Treatment
  • Enhanced CRISPR-based Screening and Research Tools Drive Demand for Advanced Genetic Research Solutions
  • The Expansion of Genomic Data Infrastructure and Bioinformatics Strengthens Market Demand for CRISPR and Cas Integration
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World CRISPR and Cas Genes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for CRISPR and Cas Genes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Libraries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Libraries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Design Tool by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Design Tool by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Cell Line Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Cell Line Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for gRNA Design & Synthesis & Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for gRNA Design & Synthesis & Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Screening Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Screening Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Biotechnology & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Academic & Government Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Biomedical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Biomedical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Agricultural Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Agricultural Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 30: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 34: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: USA 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • CANADA
  • TABLE 36: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 40: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Canada 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • JAPAN
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 42: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 46: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Japan 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • CHINA
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 48: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: China 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 52: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: China 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • EUROPE
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 54: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for CRISPR and Cas Genes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 58: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Europe 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 60: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Europe 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • FRANCE
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 64: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: France 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 66: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: France 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • GERMANY
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 70: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Germany 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 72: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Germany 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 76: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Italy 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 78: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Italy 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • UNITED KINGDOM
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 82: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: UK 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 84: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: UK 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • REST OF EUROPE
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • ASIA-PACIFIC
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • REST OF WORLD
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Addgene
  • Agilent Technologies
  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • CRISPR Therapeutics
  • Editas Medicine
  • GenScript
  • Horizon Discovery (PerkinElmer)
  • Integrated DNA Technologies (IDT)
  • Intellia Therapeutics
  • Locus Biosciences
  • Mammoth Biosciences
  • Merck KGaA
  • New England Biolabs
  • Origene Technologies
  • Sangamo Therapeutics
  • Synthego Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific

Table Information